- Home
- NVNI vs CGTX Comparison
NVNI vs CGTX Comparison
Compare NVNI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVNI | CGTX |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Brazil | United States |
| Employees | 618 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVNI | CGTX |
|---|---|---|
| Price | $1.33 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 83.8K | ★ 624.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.22 |
| 52 Week High | $4.94 | $3.83 |
Technical Indicators
Market Signals| Indicator | NVNI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 52.08 |
| Support Level | $1.10 | $1.00 |
| Resistance Level | $1.64 | $1.19 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 40.00 | 80.56 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.